16,010 Shares in Medpace Holdings, Inc. $MEDP Purchased by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. purchased 16,010 shares of Medpace Holdings, Inc. for approximately $5,025,000 during the 2nd quarter, owning 0.06% of the company after the acquisition.
• CEO August J. Troendle sold 48,487 shares of Medpace stock for about $21.9 million, indicating a 4.80% decrease in his ownership.
• Analysts have mixed ratings for Medpace, with three ratings being a Buy, twelve a Hold, and three a Sell, reflecting a consensus rating of "Hold" with an average price target of $422.27.

Robeco Institutional Asset Management B.V. bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,010 shares of the company's stock, valued at approximately $5,025,000. Robeco Institutional Asset Management B.V. owned 0.06% of Medpace as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Medpace by 37.1% during the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after acquiring an additional 83 shares during the period. Inspire Investing LLC acquired a new stake in Medpace in the first quarter valued at approximately $2,059,000. Voya Investment Management LLC grew its holdings in Medpace by 7.6% in the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company's stock valued at $6,696,000 after purchasing an additional 1,560 shares during the period. Zeno Equity Partners LLP grew its holdings in Medpace by 2.6% in the first quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company's stock valued at $18,983,000 after purchasing an additional 1,564 shares during the period. Finally, United Services Automobile Association acquired a new stake in Medpace in the first quarter valued at approximately $500,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO August J. Troendle sold 48,487 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares in the company, valued at approximately $434,803,569.35. This trade represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock valued at $74,111,427 in the last 90 days. 20.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have commented on MEDP shares. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Rothschild Redb lowered Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. Robert W. Baird raised their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Barclays lifted their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of "Hold" and an average target price of $422.27.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $530.30 on Tuesday. The business's 50 day moving average price is $476.38 and its 200-day moving average price is $369.78. The firm has a market capitalization of $14.90 billion, a PE ratio of 39.43, a P/E/G ratio of 3.35 and a beta of 1.40. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $547.15.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same period in the previous year, the company posted $2.75 earnings per share. The business's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.